GlycoMimetics Inc (GLYC)
1.71
-0.14
(-7.82%)
USD |
NASDAQ |
Apr 25, 16:00
1.70
-0.01
(-0.58%)
Pre-Market: 20:00
GlycoMimetics Free Cash Flow (Quarterly): -7.616M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -7.616M |
September 30, 2023 | -8.691M |
June 30, 2023 | -6.985M |
March 31, 2023 | -11.61M |
December 31, 2022 | -7.912M |
September 30, 2022 | -8.620M |
June 30, 2022 | -16.27M |
March 31, 2022 | -13.74M |
December 31, 2021 | -12.81M |
September 30, 2021 | -16.95M |
June 30, 2021 | -13.62M |
March 31, 2021 | -14.13M |
December 31, 2020 | -9.724M |
September 30, 2020 | -11.52M |
June 30, 2020 | -14.56M |
March 31, 2020 | -3.508M |
December 31, 2019 | -12.81M |
September 30, 2019 | -13.47M |
June 30, 2019 | -11.47M |
March 31, 2019 | -14.39M |
December 31, 2018 | -10.04M |
September 30, 2018 | -10.11M |
Date | Value |
---|---|
June 30, 2018 | -13.08M |
March 31, 2018 | -10.23M |
December 31, 2017 | -8.403M |
September 30, 2017 | -6.263M |
June 30, 2017 | -6.272M |
March 31, 2017 | -9.125M |
December 31, 2016 | -6.393M |
September 30, 2016 | -7.697M |
June 30, 2016 | -7.098M |
March 31, 2016 | -9.247M |
December 31, 2015 | -6.961M |
September 30, 2015 | 13.51M |
June 30, 2015 | -6.348M |
March 31, 2015 | -8.707M |
December 31, 2014 | -6.169M |
September 30, 2014 | -4.856M |
June 30, 2014 | 9.132M |
March 31, 2014 | -2.601M |
December 31, 2013 | -5.578M |
September 30, 2013 | -3.428M |
June 30, 2013 | -2.731M |
March 31, 2013 | -3.883M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-16.95M
Minimum
Sep 2021
-3.508M
Maximum
Mar 2020
-11.37M
Average
-11.61M
Median
Mar 2023
Free Cash Flow (Quarterly) Benchmarks
Altimmune Inc | -16.53M |
Cellectar Biosciences Inc | -9.862M |
PDS Biotechnology Corp | -8.457M |
Syros Pharmaceuticals Inc | -18.60M |
Precision BioSciences Inc | -8.418M |